8. H., et al., Outcome of community-acquired pneumonia: influence of age, European Respiratory Journal, 2008. residence status and antimicrobial treatment. 32(1): p. 139. 9. Newall, A.T., et al., The potential cost-effectiveness of infant pneumococcal vaccines Vaccine, 2011. 29(45): p. 8077-8085. in Australia. 10. Dirmesropian, S., et al., Cost-effectiveness of 13-valent pneumococcal conjugate Vaccine, 2017. 35: p. 4307 - 4314. vaccine (PCV13) in older Australians. 11. Australian Institute of Health and Welfare. Health expenditure Australia 2015–16 2016 ; Available from: .
8. H., et al., Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. European Respiratory Journal, 2008. 32(1): p. 139. 9. Newall, A.T., et al., The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine, 2011. 29(45): p. 8077-8085. 10. Dirmesropian, S., et al., Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. Vaccine, 2017. 35: p. 4307 - 4314. 11. Australian Institute of Health and Welfare. Health expenditure Australia 2015–16 2016 ; Available from: .